According to the findings of a clinical trial supported by the National Institutes of Health (USA), two drugs commonly used to treat adults with heart failure – furosemide and torsemide – showed no difference in their ability to improve patient survival when compared.
The trial, titled Torsemide Comparison with Furosemide for Management of Heart Failure (TRANSFORM-HF), is one of the largest to date studying common drugs in heart failure. It helps answer the age-old question of which medication is superior for treating this group of patients having a high mortality risk. The findings from the trial are of clinical relevance and highlight the need for more effective life-saving therapies for heart failure patients.
The study was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, and published in the Journal of the American Medical Association.
Source: www.nih.gov
